throbber
United States Patent
`
`[19]
`
`Sehgal et al.
`
`[54]
`
`[75]
`
`USE OF RAPAMYCIN IN TREATLIENT OF
`TUMORS
`
`Inventors: Surendra N. Sehgal, Princeton, N.J.;
`Claude Vezina, Oka, Canada
`
`Assignee:
`
`Ayerst, McKenna & Harrison, Inc.,
`St. Laurent, Canada
`
`Appl. No.:
`Filed:
`
`784,274
`Oct. 29, 1991
`
`Related U.S. Application Data
`Continuation-in-part of Ser. No. 682,813, Apr. 9, 1991,
`Pat. No. 5,066,493, which is a continuation-in-part of
`Ser. No. 391,334, Aug. 9, 1989. abandoned, which is a
`division of Ser. No. 592,193, Mar. 22, 1984, Pat. No.
`4,885,171, which is a continuation of Ser. No. 126,276,
`Mar. 3, 1980, abandoned, which is a continuation of
`Ser. No. 957,626, Nov. 3, 1978, abandoned.
`
`Int. Cl.-‘5 ..................... A6lK 35/00; A61K 31/66;
`A61K 31/505; AOIN 57/00
`U.S. Cl. .................................... 424/122; 514/110;
`514/274; 514/291
`Field of Search .............. .. 424/ 122; 514/110, 274,
`514/291
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2/1976 Sehgal .......................
`3,929,992
`3,993,749 11/1976
`4,316,885
`3/1982
`4,401,653
`8/1983
`4,650,803
`3/1987
`
`424/122
`424/122
`.. 424/122
`.. 424/114
`
`llilll||||1|1|llllllllIllll|||||1l||ll|||||ll|1|||||lllllllllllllllllllllll
`
`USO05206018A
`
`111]
`
`[45]
`
`Patent Number:
`
`5,206,018
`
`Date of Patent:
`
`Apr. 27, 1993
`
`................... 424/122
`4,885,171 12/1989 Surcndra et al.
`. 424/122
`5,066,493 11/1991 Sehgal
`. 424/ 122
`5,078,999
`1/1992 Warner
`5,080,899
`1/1992 Sturm .............................. 424/122
`OTHER PUBLICATIONS
`
`US. patent application. Ser. No. 07/717,773 filed Jun.
`18, 1991—(Miller).
`Abst. dist. at Fifth Intl Conf. of Inflamm. Res. Assoc.
`121, Sep. 23, 1990 (Baeder, W. L.).
`'
`Vezina, C. J. Antibiot. 28, 721-726 (1975).
`Sehgal, S. J. Antibiot. 28, 727-732 (1975).
`Martel. R., Can J. Physiol. Pharmacol., 55, 48 (1977).
`Eng. C. J. Antibiotics 37:l23l (1984).
`FASEB 3:3411 (1989)-——(Staruch, M. J.).
`FASEB 3:5256 (1989)—(Dumont, F. 1.).
`Med. Sci. Res. _l7:877 (1989)—(Morris, 11.).
`Primary Examz‘ner—Nathan M. Nutter
`Attorney, Agent, or Firm—Arnold S. Milowsky
`
`ABSTRACT
`[57]
`This invention provides a method of treating, inhibiting
`the proliferation of, reducing the size of, or eradicating
`malignant neoplasms in a mammal
`in need thereof
`which comprises
`administering
`an
`antineoplastic
`amount of rapamycin to said mammal. In particular,
`rapamycin is useful in treating, inhibiting the prolifera-
`tion of, reducing the size of, or eradicating malignant
`mammary and skin carcinomas, and central nervous
`system neoplasms.
`
`12 Claims, No Drawings
`
`West-Ward Pharm.
`Exhibit 1044
`Page 001
`
`

`

`1
`
`5,206,018
`
`USE OF RAPAMYCIN IN TREATMENT OF
`TUMORS
`
`This a continuation-in-part application of co-pending
`application Ser. No. 07/682,813, filed Apr. 9, 1991 and
`now U.S. Pat. No. 5,066,493, which in turn is a con-
`tinuation-in-part application of co-pending application
`Ser. No. 07/391,334, filed Aug. 9, 1989 and now aban-
`doned, which intum is a divisional application of co-
`pending application Ser. No. 06/592,193, filed on Mar.
`22, 1984, now issued as U.S. Pat. No. 4,885,171, on Dec.
`5, 1989, which in turn is a continuation application of
`co-pending application Ser. No. 06/126,276, filed on
`Mar. 3, 1980, now abandoned, which in turn is a contin-
`uation application of co-pending application Ser. No.
`05/957,626, filed Nov. 3, 1978, now abandoned.
`BACKGROUND OF THE INVENTION
`1. Field of the Invention
`This invention relates to the use of rapamycin as an
`anti-cancer or anti-tumor agent,
`2. Description of the Prior Art
`Rapamycin is an antifungal antibiotic described by C.
`Vezina et al., J. Antibiot., 28, 721 (1975), S. N. Sehgal et
`al., J. Antibiot., 28, 727 (1975) and S. N. Sehgal et al.,
`U.S. Pat. No. 3,929,992, issued Dec. 30, 1975, filed Apr.
`12, 1974. Rapamycin is extracted from a streptomycete
`(Streptomyces hygroscopicus)
`isolated from an Easter
`Island soil sample and is particularly effective against
`Candida albicans both in vitro and in vivo.
`In addition, a recent report by R. R. Martelet al.,
`Can. J. Physiol., 55, 48 (1977) describes the use of rapa-
`mycin for the prevention of the development of two
`experimental
`immunopathies
`[(experimental allergic
`encephalomyelitis (EAE) and adjuvant arthritis (AA)].
`The latter report also describes the inhibitory effect of
`rapamycin on the formation of humoral (IgE-like) anti-
`body. This report concludes that immunosuppressant
`activity of rapamycin appears to be related to inhibition
`of the lymphatic system.
`SUMMARY OF THE INVENTION
`
`According to this invention a method is provided for
`treating malignant neoplasms in a mammal which com-
`prises administering to said mammal an antineoplastic
`amount of rapamycin. More specifically, rapamycin
`inhibits the proliferation of malignant cells, controls the
`growth of malignant neoplasms, reduces the size of
`malignant neoplasms, eradicates malignant neoplasms,
`prolongs the survival time of said mammal, kills malig-
`nant cells, and adversely affects malignant cells.
`DETAILS OF THE INVENTION
`
`According to the present method, rapamycin is em-
`ployed as the active agent. The isolation and description
`of rapamycin is given in U.S. Pat. No. 3,929,992, cited
`above, herein incorporated by reference.
`Rapamycin is administered, either orally or parenter-
`ally, to a carcinogenic tumor bearing mammal for the
`purpose of inhibiting the proliferation of malignant
`cells, controling the growth of malignant neoplasms,
`reducing the size of malignant neoplasms, eradicating
`malignant neoplasms, prolonging the survival time of
`said mammal, killing malignant cells, and adversely
`affecting malignant cells.
`While rapamycin can be administered above, e.g. as a
`sole component of a filled capsule, it is preferred to
`
`5
`
`10
`
`15
`
`20
`
`25
`
`35
`
`50
`
`65
`
`2
`formulate the compound in various dosage forms for
`oral or parenteral administration, e.g. tablets or sterile
`solutions. Such formulations are described in U.S. Pat.
`No. 3,929,992, cited above. Rapamycin may also be
`administered in combination with a therapeutically ef-
`fective amount of an antineoplastic agent commonly
`used in cancer therapy.
`When the antifungal antibiotic of this invention is
`employed as an anticancer agent in warm-blooded ani-
`mals, e.g. rats, it may be used alone or in combination
`with a therapeutically effective amount of an antineo-
`plastic agent commonly used in cancer therapy and
`with pharmaceutically acceptable carriers, the propor-
`tion of which is determined by the solubility and chemi-
`cal nature of the compounds, chosen route of adminis-
`tration and standard biological practice. For example,
`an antineoplastic effective amount of the antibiotic may
`be administered alone or in combination orally in solid
`form containing such excipients as starch, sugar, certain
`types of clay and so forth. Similarly, such an amount
`may also be administered orally in the form of solutions
`or suspensions, or the antibiotic may be injected paren-
`terally alone or in combination. For parenteral adminis-
`tration the antibiotic may be used alone or in combina-
`tion in the form of a sterile solution or suspension con-
`taining other solutes or suspending agents, for example,
`enough saline or glucose to make the solution isotonic,
`bile salts, acacia, gelatin, sorbitan monooleate, polysor-
`bate 80 (oleate esters of sorbitol and its anhydrides co-
`polymerized with ethylene oxide) and the like.
`When utilizing rapamycin alone or in combination
`with a therapeutically effective amount of an antineo-
`plastic agent commonly used in cancer therapy for the
`treatment of tumors, the total dose of active agent can
`range from 0.01 to 250 mg per kg of body weight per
`day with a preferred dosage range from 0.1 to 50 mg per
`kg of body weight per day. However, as the dosage of
`rapamycin to be administered by the method of this
`invention will of course vary with the tumor or cancer
`and tolerance of the mammal, and with the nature of the
`other antineoplastic agents used in combination. The
`schedule of dosing can range from one to five times per
`day to a single dose given every two to ten days. In-
`creasing the frequency of administration is expected to
`reduce the amount of active drug needed per dose. Such
`dosages and scheduling of administration must be deter-
`mined on an individual basis, depending upon the tumor
`or cancer, nutritional state of the mammal, age of the
`mammal, toxicity in each individual, and with the na-
`ture of the other antineoplastic agents used in combina-
`tion, etc.
`Rapamycin was evaluated in several National Cancer
`Institute standard tumor test procedures. The results
`showed that rapamycin reduces tumor size in and pro-
`longs the survival
`time of tumor-bearing mammals.
`More specifically, rapamycin is useful for controlling
`the following carcinogenic tumors in standard mamma-
`lian tumor models: lymphatic leukemia, colon, mam-
`mary, melanocarcinoma and ependymoblastoma. The
`effectiveness of rapamycin in this respect was demon-
`strated in the laboratory with rodents having trans-
`planted tumors. Details of methods used to evaluate this
`effect are described in various publications; for exam-
`ple, R. I. Geran et a.l., Cancer Chemother. Rep., Part 3,
`3, (No. 2) 1-103 (1972) and references therein. In addi-
`tion, the protocols for the antitumor tests are available
`from the National Cancer Institute, Bethesda, Md.,
`U.S.A. These models have been adopted by the Na-
`
`-
`
`West-Ward Pharm.
`Exhibit 1044
`Page 002
`
`

`

`5,206,018
`
`3
`tional Cancer Institute as standard test procedures for
`predicting clinical activity of new chemotherapeutic
`agents.
`,
`Tables 1 to 6 show the effects of therapy with rapa-
`mycin on various tumors or cancers in rodents. More
`specifically, Table 1 shows the prolongation of survival
`time of female CDF1 mice implanted with lymphatic
`leukemia P388 by administering rapamycin; Table 2
`shows the reduction in size of colon 38 tumors in female
`BDF1 mice by administering rapamycin; Table 3 shows
`the prolongation of survival time of male CDF1 mice
`'
`‘
`'
`‘
`‘
`
`4
`TABLE 3mnfinued
`Effect ornxpamycin on Suwim _nm°fCDF1Mi“
`.
`Implanted with Colon 26 Tumor
`Dose, Am wt Dmmnm
`MST
`1nj_
`ofA_njm3]5
`4.5
`mg/kg
`(1-.c, g)
`12.5
`03
`Tmmcm:
`Single intraperitoneal injection on days 1, 5 and 9 in a vehicle oftaline with Tween.
`:_:°;_lm_m_
`1'/cg, = Lugs... n.,..;.,.i .5... (M51) in days or mm .ni..n1. (F)/wntrol
`'
`.
`
`teriseonaideredaaangn1.fiaant''
`lon-
`«-wr
`"'°
`
`survivor;
`on my 5
`10/10
`
`T
`30.4
`
`c
`19_1
`
`1"/car,
`Msr
`159
`
`mammary tumors i.n male CDBF1 rats by administering
`TABLE 4
`rapamycin; Table 5 shows the prolongation of survival
`Effect or Rspamvcin 0" CDSF1
`time of female BDF1 mice implanted with B16 melono-
`
`carcinoma by administering rapamycin; and Table 6 — T““‘°“ i“ CD": R“
`-
`'
`'
`'
`Average
`shows the prolongation of survival time of male Swiss
`/ Net wt‘ Dificmcc
`MTW
`mice implanted with ependymoblastoma by administer- 20
`O1-Animus
`WE
`‘"3 "aPamY°i“-
`Cr-c, g)
`—-6.6
`15:?
`-4.1
`_2.4
`-0.3
`
`Suwivm
`on Day 5
`4/10
`ifififi
`10/10
`10/10
`10/10
`
`T
`c
`0
`3200
`35% 3%
`755
`3200
`325
`31“)
`923
`3200
`
`In}
`mg/kg -
`400
`0
`50
`25
`12.5
`Truman‘:
`Single intraperiional injection on days 1, 8. l5. 22 and 29 in a vehicle ofsaline with
`T"’°°°"‘°-
`Evaluation:
`T/C7-. - Median tumor we‘1ght(M'I'W) estimated from tumor diameter oftreated
`animals (T)/control animals (C) x 100. A T/C% or 42 or less is considered as a
`significant inhibitor of tumor growth. Evaluation done on day 30.
`
`-1-/C%
`MTW
`
`19
`23
`25
`29
`
`25
`
`TABLE 1
`’i$°i‘..‘.’.‘...i““.3I‘.‘;“’i°”‘°:.‘I?‘”£:.?J"’;°p°§§°f.1..”§i°*'
`_i__
`‘
`“
`°““
`AVG. W1. Difference
`MST
`of Animals
`Survivors __d.aL_ 170%
`(T-C, g)
`on Day 5
`T
`C
`MST
`_1g
`5/6
`14_]
`101
`133
`-2.4
`6/6
`13.1
`10.2
`128
`‘ 1‘
`5/5
`13-7
`1°-2
`134
`- L9
`6/6
`14-3
`10-1
`140
`— 1.6
`6/6
`13.9
`10.2
`136
`-0.6
`6/6
`13.9
`"102
`136
`
`DOS€/
`mi
`mg/kg
`400
`200
`‘°°
`50
`25
`12.5
`r Treatment:
`injections starting on day one in 11 vehicle of saline with
`Nine iniraperitoneal
`Tween-B0 [Trade Mark for a derivative of Z-sorbitan mono-9-ociadecenoate po|y- 35
`(oxy~l.2-etliancdiyl)].
`Evaluation:
`‘
`T/C% = Median Survival Time (MST) in days of treated animals (T)/control
`animals (C) X 100. A T/C% of 125 or greater is considered as a significant prolon-
`gatiun of host survival. Evaluation done on day 30.
`
`5
`Effect of-R3 am Gin on E16 Mdanocucinoma in BDF Mice
` 1j—
`Avcrfgc
`Dosel
`NC! Wt. Difference
`MST
`of Animals
`Inj.
`dais
`mg/kg
`(T_C. g.)
`‘lo 400
`-3.3
`200
`-1.5
`
`Survivors
`on Diy 5
`10/10
`10/10
`
`T
`22.0
`22.3
`
`C
`20.1
`20.1
`
`T/C%
`MST
`109
`ll0
`
`TABLE2
`
`:
`0.1
`0.1
`
`10/10
`10/10
`
`23.0
`29.0
`
`20.1
`20.1
`
`139
`144
`
`133
`Effect of Rapamycin on Colon 38 Tumor Weight in Mice
`25
`D°5=/ Ave-W1-Difference
`MTW
`12.5
`ofmiimals
`Survivors _2s¥ T/C%
`Ini
`mg/kg
`(T—C, g)
`on Day 5
`T
`C
`MTW 45 Truman
`400
`_3_4
`10/10
`133
`310
`23
`Single intraperitoni.-al injection on each of days I through 9 in a vehicle of aaline
`with Tween-80.
`200
`-2.0
`I0/10
`209
`810
`25
`Evdmdon:
`10°
`’°-3
`“V1°
`272
`31°
`33
`T/C% = Median Survival Time (MST) in days of treated animals ('1) control
`50
`-0.3
`9/10
`320
`310
`39
`animals (c) x 100. A r/car, of 125 or grater is considered as atignificant prolon-
`25
`-0.4
`IO/10
`368
`310
`45
`prion of host survival. Evaluation done on day 60.
`12.5
`0.4
`10/10
`363
`810
`45
`Treatment:
`Single intnperiloneal injection on days 2, 9 and 16 in a vehicle ofsaline with Tween
`Evaluation:
`30'
`_
`T/C% = Median tumor weight (MTVV) mtimated from tumor diameter of treated 55
`animals (T)/control animals (c) x 100. A T/C% of 42 or les is oonidered Is a
`significant inhibitor of tumor growth. Evaluation done on day 20.
`
`TABLE 3
`_
`,
`,
`_
`Effect of Rapamycin on Survival Time of CDF1 Mice
`1!“ ‘Med with C010" 25 T“m°r
`Dosel Ave. Wt. Difference
`MST
`Inj.
`of Animals
`__cl__ay§___ T/C%
`mg/kg
`(T-C, g)
`T
`C
`MST
`400
`-2.4
`26.3
`19.!
`137
`200
`-1.8
`25.8
`19.1
`135
`I00
`-1.4
`29.0
`l9.l
`151
`5o
`._o_g
`3115
`19‘;
`150
`25
`—-0.3
`30.3
`19.1
`158
`
`Survivors
`on Day 5
`10/10
`10/ 10
`IO/10
`10/10
`10/10
`
`Survivors
`on Day 5
`10/10
`10/10
`9/10
`10/10
`10/10
`
`TABLE 6
`Effect of Ragycin on Egdmoblastoma in Swiss Mice
`Averfge
`Dose/ Net Wt. Difference
`of Animals
`In].
`mg/kg
`(PC. 8)
`200
`-3.3
`100
`-2.2
`50
`_l‘3
`25
`-2.0
`12.5
`-1.0
`Tmmml:
`Single intraperitoneal injection on inch of days I through 9 in a vehicle of aaline
`with Tweenvflio.
`Evdumrum
`T/C% = Median Survival Time (MST) in days or treated animals (n control
`animals (C) x ICO. A ‘!'/C% of 125 or grater is considered as a significant prolon-
`gaiion of host survival. Evaluation done on day 60.
`
`MST
`dlxg
`
`T
`44.0
`26.0
`343
`34.0
`32.3
`
`C
`18.1
`18.1
`13.1
`13.1
`13.1
`
`T/C%
`MST
`243
`I43
`‘S7
`137
`173
`
`West-Ward Pharm.
`Exhibit 1044
`Page 003
`
`

`

`5,206,018
`
`5
`The standard animal models used can be divided into
`two types based on how the results are expressed. Re-
`sults can be expressed as a comparison of the median
`survival time for mammals in the treated (T) group
`(those treated with rapamycin) versus the median sur-
`vival time for mammals in the untreated control (C)
`group. The result is given as a percentage of T/C; a
`high percent T/C indicates that the compound that was
`tested was effective in treating the malignant neoplasm
`that was evaluated. Statistically significant results are
`observed at either 125 or 130% T/C, depending on the
`neoplasm that was evaluated. Alternatively, the results
`of certain tests for solid tumors can be expressed based
`on the tumor weight of the solid tumor after the evalua-
`tion period. The tumor weight in the test (T) animals is
`compared with the tumor in the control (C) animals and
`the results are expressed as a percent T/C. When results
`are expressed as a function of tumor weight, a low %
`T/C indicates effective treatment of the neoplasm, as
`the tumors in the test animals are smaller than tumors in
`the untreated control animals. A percent T/C of less
`than 42 is considered to be statistically significant.
`The results of the above described National Cancer
`Institute standard tumor test procedures demonstrate
`rapamycin's antineoplastic activity in mammals. As
`such rapamycin is useful
`in treating malignant neo-
`plasms. Treating broadly includes, but is not limited to,
`inhibiting the proliferation of malignant cells, control-
`ling the growth of malignant neoplasms, reducing the
`size of malignant neoplasms, eradicating malignant neo-
`plasms, prolonging the survival time of said mammal,
`killing malignant cells, and adversely affecting malig-
`nant cells. Preferred embodiments of this invention, that
`are described below, are based on the specific types of
`malignant neoplasms that rapamycin has been shown to 35
`be effective in treating. The scope of this invention,
`however, is not limited to these specific embodiments,
`as other neoplasms that rapamycin is effective in treat-
`ing will be apparent to one skilled in the art.
`Based on the ability of rapamycin to significantly
`inhibit tumor growth in the Colon 38 standard test pro-
`cedure, as seen by a reduction in tumor size, and in-
`crease survival time of the host mammal in the Colon 26
`standard test procedure, rapamycin is useful in treating
`mammalian carcinomas of the colon and rectum. The
`use of rapamycin in treating colon cancer is covered in
`U.S. Pat. No. 4,885,171.
`In the CDSF1 mammary tumor test procedure, rapa-
`mycin caused a reduction in tumor size at doses of up to
`200 mg/kg. Mammary minors were reduced in weight
`by 71% at 12.5 mg/kg and by 90% at a dose of 200
`mg/kg, indicating an almost complete eradication of the
`mammary carcinoma. As such, rapamycin is useful in
`treating mammalian breast neoplasms.
`A significant increase in survival time of the host
`mammal was observed in the B16 melanocarcinoma
`standard test procedure for mice that were treated with
`doses of up to 100 mg/kg. As such, rapamycin is useful
`in treating skin carcinomas such as basal cell carcinoma,
`squamous cell carcinoma, malignant melanoma, and the
`like.
`The ependymoblastoma standard test procedure is
`predictive of a compound’s ability to treat malignant
`central nervous system neoplasms. At a dose of 50
`mg/kg, a % T/C of 187 was obtained, and at a dose of 65
`200 mg/kg, a % T/C of 243 was obtained (median
`survival time of 4-4.0 days for mammals treated with
`rapamycin versus median survival time of 18.1 days for
`
`-
`
`6
`untreated control group). At all doses tested, rapamycin
`caused a significant increase in survival time of the host
`mammal in the ependymoblastoma standard test proce-
`dure, and is therefore useful in treating malignant cen-
`tral nervous system neoplasms. The extremely favor-
`able results obtained in this test procedure also indicate
`that rapamycin is capable of reaching the intracranial
`neoplasm by crossing the blood brain barrier. Malignant
`central nervous system neoplasms describes a broad
`class of intracranial neoplasms which include, but are
`not
`limited to:
`intracranial meuingiomas, sarcomas,
`gliomas,
`astrocytomas, medulloblastomas,
`schwan-
`nomas, ependymomas, meningiomas, genninomas, and
`the like.
`Rapamycin was weakly active in the P-388 leukemia
`standard test procedure; a maximal % T/C of 140 was
`achieved at a dose of 50 mg/kg. When comparing these
`data to other data obtained for other anti-leukemic com-
`pounds described in the literature, rapamycin is not felt
`to be useful in treating higher mammalian leukemias.
`Rapamycin also can be used to produce beneficial
`effects in the treatment of malignant neoplasms when
`combined with a therapeutically effective amount of an
`antineoplastic agent commonly used in cancer therapy.
`Such antineoplastic agents
`include the alkylating
`agents, for example, busulfan, chlorambucil, cyclophos-
`phamide, mechlorethamine hydrochloride, melphalan,
`pipobroman, thiotepa and uracil mustard; a.ntimetabo-
`lites, for example, cytarabine, fluorouracil, floxuridine,
`mercaptopurine, methotrexate and thioguanine; miscel-
`laneous anticancer agents, for example, dacarbazine,
`hydroxyurea, mitotane, procarbazine hydrochloride,
`quinacrine hydrochloride, vinblastine sulfate and vi.n-
`cristine sulfate; estogens, for example, chlorotrianisene,
`conjugate estogens (e.g. PREMARIN ®). diethylstil-
`bestrol and the like; androgens, for example, methyltes-
`tosterone, testosterone and the like; adrenal corticoster-
`oids, for example, prednisone and the like; progester-
`gens,
`for example, megestrol, hydroxyprogesterone
`caproate and the like; radioactive isotopes; and antibiot-
`ics, for example, bleomycin sulfate, doxorubicin hydro-
`chloride and the like. Suitable methods of administra-
`tion, compositions and dosages of the antineoplastic
`agents are described in medical textbooks; for instance,
`“PI-IYSICIANS’ DESK REFERENC ”, 32nd ed.,
`Medical Economics Co., Oradell, N.J. U.S.A., 1978 and
`“AMA DRUG EVALUATIONS", 3rd ed. PSG Pub-
`lishing Company,
`Inc., Littleton, Mass, U.S.A. pp
`1106-1151, 1977. When used in combination, rapamycin
`is administered as described previously; however, a
`lower dose can be used for efficacious results.
`We claim:
`1. A method of treating a malignant neoplasm se-‘
`lected from the group consisting of a mammary carci-
`noma, a skin carcinoma, and a central nervous system
`neoplasm in a mammal in need thereof which comprises .
`administering an antineoplastic amount of rapamycin to
`said mammal orally or parenterally with the proviso
`that said malignant neoplasm has not been transplanted
`into said mammal.
`2. The method of claim 1 wherein the skin carcinoma
`is selected from the group consisting of a basal cell
`carcinoma, squamous cell carcinomas, and malignant
`melanoma.
`3. The method of claim 1 wherein the central nervous
`system neoplasm is an intracranial neoplasm selected
`from the group consisting of a meningioma, sarcoma,
`
`West-Ward Pharm.
`Exhibit 1044
`Page 004
`
`

`

`5,206,018
`
`7
`glioma, astrocytoma, medulloblastoma, schwannoma,
`ependymoma, meningioma, and germinoma.
`4. A method of inhibiting the proliferation of malig-
`nant cells selected from the group consisting of a mam-
`mary carcinoma, a skin carcinoma, and a central ner- 5
`vous system neoplasm in a mammal in need thereof
`which comprises
`administering an
`antineoplastic
`amount of rapamycin to said mammal orally or paren-
`terally with the proviso that said malignant cells have
`not been transplanted into said mammal.
`5. The method of claim 4 wherein the skin carcinoma
`is selected from the group consisting of a basal cell
`carcinoma, squameous cell carcinomas, and malignant
`melanoma.
`6. The method of claim 4 wherein the central nervous
`system neoplasm is an intracranial neoplasm selected
`from the group consisting of a meningioma, sarcoma,
`glioma, astrocytoma, medulloblastoma, schwannoma,
`ependymoma, meningioma, and germinoma.
`7. A method of reducing the size of a malignant neo-
`plasm selected from the group consisting of a mammary
`carcinoma, a skin carcinoma, and a central nervous
`system neoplmm in a mammal in need thereof which
`comprises administering an antineoplastic amount of
`rapamycin to said mammal orally or parenterally with 25
`the proviso that said malignant neoplasm has not been
`transplanted into said mammal.
`
`8
`8. The method of claim 7 wherein the skin carcinoma
`is selected from the group consisting of a basal cell
`carcinoma, squameous cell carcinomas, and malignant
`melanoma.
`9. The method of claim 7 wherein the central nervous
`system neoplasm is an intracranial neoplasm selected
`from the group consisting of a meningioma, sarcoma,
`glioma, astrocytoma, medulloblastoma, schwannoma,
`ependymoma, mening-ioma, and germinoma.
`10. A method of eradicating a malignant neoplmm
`selected from the group consisting of a mammary carci-
`noma, a skin carcinoma, and a central nervous system
`neoplasm in a mammal in need thereof which comprises
`administering an antineoplastic amount of rapamycin to
`said mammal orally or parenterally with the proviso
`that said malignant neoplasm has not been transplanted
`into said mammal.
`11. The method of claim 10 wherein the skin carci-
`noma is selected from the group consisting of a basal
`cell carcinoma, squameous cell carcinomas, and malig-
`nant melanoma.
`12. The method of claim 10 wherein the central ner-
`vous system neoplasm is an intracranial neoplasm se-
`lected from the group consisting of a meningioma, sar-
`coma, glioma, astrocytoma, medulloblastoma, schwan-
`noma, ependymoma, meningioma, and germinoma.
`t
`t
`I
`t
`#
`
`West-Ward Pharm.
`Exhibit 1044
`Page 005
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket